Posted by Michael Wonder on 19 Apr 2021
Darzalex SC becomes the first and only Health Canada approved treatment for patients with newly diagnosed light chain amyloidosis, a rare disease
19 April 2021 - Darzalex SC combination regimen is supported by the Phase 3 ANDROMEDA study demonstrating a significantly higher haematologic complete response rate in this rare and serious blood cell disorder.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today Health Canada approved Darzalex SC (daratumumab injection), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone for the treatment of adult patients with newly diagnosed light chain amyloidosis.
